Aging Cell 'Under Review': What Each Status Means and When to Expect a Decision

Aging Cell operates the Wiley Editor-in-Chief + Supervising Editor + editorial board model, led by multiple co-Editors-in-Chief. The Editor-in-Chief reviews each submission with the advice of the editorial board, then chooses a Supervising Editor in an appropriate field of interest to supervise the peer review. Verify the current Editors-in-Chief on the journal's editorial-team page before quoting any name in a cover letter.

A Supervising Editor at Aging Cell typically handles 30 to 60 manuscripts per year and spends 30 to 60 minutes on the initial read; Aging Cell Supervising Editors are active aging researchers fitting Aging Cell editorial work around their own laboratories.

Aging Cell editorial culture is decisive: the 5 to 10 day desk-screen notification + 4-week first-decision target reflects Wiley's rapid editorial response. The Editor-in-Chief and Supervising Editor structure means a paper is judged first on aging-biology priority, then on whether the mechanism, model system, and reviewer pool are strong enough for the journal's field-of-interest routing.

Functionally, the Supervising Editor becomes the handling editor for reviewer routing once the paper clears the EIC screen. For authors, that makes the abstract, model justification, and first figure unusually important. Papers that pass the Aging Cell EIC + editorial board desk screen have cleared the steepest filter in Wiley aging-biology publishing.

Before the paper reaches external reviewers, the Aging Cell Editor-in-Chief evaluates each submission with the advice of the editorial board. About 40 to 50 percent of submissions are desk-rejected at this stage within 5 to 10 days. A desk rejection most often means the EIC and editorial board concluded that the work would fit better at a sister Wiley aging-biology journal (Aging Brain for neuro-aging, GeroScience for geriatric science) or that the aging biology priority bar is not met.

The Aging Cell editorial office confirms files are complete: manuscript with figures embedded, Supporting Information with aging biology characterization data, Wiley template formatting, reporting checklists where applicable (ARRIVE for animal aging work, MIQE for quantitative PCR), cover letter directed to the EIC, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, and data-availability statement.

The Editor-in-Chief reads the paper and evaluates aging biology priority, mechanism contribution, and Aging Cell subspecialty routing across cellular senescence, mitochondrial aging, proteostasis, autophagy, stem-cell aging, and aging biomarkers. The EIC consults with the editorial board for ambiguous-fit papers.

In parallel with the EIC's primary read, ambiguous-fit papers are discussed with the editorial board where peer board members weigh in on whether the paper would fit better at Aging Cell flagship or at sister Wiley aging journals. This editorial board discussion runs alongside the desk-screen and adds 2 to 5 days to the timeline that is invisible to the author in the portal.

Papers that pass the EIC + editorial board screen are assigned to a Supervising Editor in an appropriate field of interest. The Supervising Editor invites 2 to 3 reviewers with topic-matched aging biology subspecialty expertise.

Once reviewers agree to review, the typical Aging Cell peer-review cycle lasts 2 to 4 weeks per reviewer per Wiley's 4-week first-decision target. Reviewers are asked to evaluate aging biology mechanism, methodology rigor, and reproducibility. Reviewer reports for Aging Cell tend to be focused; 1500 to 3000 word reports are typical given the 4-week target.

After reports return, the Supervising Editor synthesizes them and presents the case to the EIC for final decision. Total submission-to-acceptance commonly runs 3 to 6 months for successful papers, including revision rounds.

• Rejection within 1 to 5 days: Administrative issue or immediate scope mismatch.

• Rejection within 5 to 10 days: EIC + editorial board desk rejection per the 5 to 10 day notification target.

• Still Under Review after 2 weeks: Strong signal. Paper passed the EIC + editorial board desk screen.

• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the ScholarOne portal is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 week.

This is the most common anxiety we hear from Aging Cell authors during the active editorial window. The honest answer: no, 4 weeks at Under Review puts you right at Aging Cell's 4-week first-decision target. Reports may already be in editorial synthesis with the Supervising Editor preparing the recommendation for the EIC. Most reviewer-driven delays come from reviewer-recruitment timing for aging biology subspecialty experts rather than slow reviews.

If the portal still says Under Review at the 6-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the Supervising Editor granted it. This is normal practice at Aging Cell.

What you should NOT do during the 4-to-6-week window is email the editorial office. Aging Cell Supervising Editors are active aging researchers managing 30+ active papers per year around their own laboratories; an inquiry at 4 weeks adds friction without accelerating the timeline.

If your Aging Cell paper is rejected after review, the natural cascade depends on what the reviewers and Supervising Editor cited:

Aging Brain is the natural Elsevier cascade for neuro-aging papers (Aging Brain is published by Elsevier in collaboration with Wiley's Aging Cell editorial team).

GeroScience is the Springer cascade for geriatric science papers.

Nature Aging is the external Springer Nature top-tier aging cascade. The Nature Aging Manuscript Tracking System at mts-natage.nature.com handles submission; nataging@nature.com handles publisher-level inquiries.

npj Aging is the Nature Portfolio open-access aging cascade.

Cell Metabolism is the Cell Press metabolism cascade for metabolic aging work. Cell Press uses Editorial Manager at Editorial Manager submission portal; editorial contact cellmetabolism@cell.com.

eLife is a cascade option for aging biology under the Reviewed Preprint model.

Wiley asks reviewers at Aging Cell to evaluate four things specifically. The table below maps each to actionable preparation.

Across Aging Cell manuscripts, we see three patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the desk screen. These are Manusights observations from aging-biology and cell-biology manuscripts prepared for Wiley and neighboring journals, not hidden Wiley decision data.

Phenotype-first framing makes the paper feel smaller than Aging Cell. Many drafts show a real aging-associated phenotype, but the abstract reads like a disease-model or intervention paper rather than an aging-biology mechanism paper. Aging Cell reviewers usually need to see how the result changes understanding of senescence, proteostasis, mitochondrial function, stem-cell aging, inflammation, autophagy, epigenetic drift, or another aging process. The strongest manuscripts state the aging mechanism early, then use the model system as evidence for that mechanism rather than as the whole contribution.

Model-system detail often determines reviewer confidence. In aging manuscripts, the same result can be interpreted differently depending on age, sex, strain, diet, housing, randomization, blinding, power, frailty, intervention timing, and endpoint definition. When those details are scattered or missing, reviewers spend their attention on credibility instead of the biological claim. Stronger submissions make the animal or cellular model auditable in the Methods and Supporting Information before the reviewer asks.

Marker panels need orthogonal support. Aging Cell manuscripts often rely on senescence markers, autophagy markers, mitochondrial readouts, inflammatory signatures, or omics-derived biomarkers. Reviewer skepticism rises when one marker or one imaging panel carries a broad biological conclusion. Better papers pair marker data with functional rescue, genetic perturbation, longitudinal evidence, independent cohort validation, or raw-data availability that makes the interpretation reproducible.

Source limitation: Manusights cannot see private Wiley reviewer assignments, queue state, or editor notes. This page combines official Wiley guidance, public timing/status information, and Manusights pre-submission review patterns; the Aging Cell ScholarOne record remains the authority for your manuscript.

This page was created from Wiley's public Aging Cell author guidelines at Wiley author instructions, Wiley editorial documentation (5 to 10 day desk-screen notification target, 4-week first-decision target, EIC + Supervising Editor model with editorial board advice, single-blind peer review, multiple co-Editors-in-Chief), and Manusights pre-submission review experience with Aging Cell-targeted manuscripts.

For authors, this page translates the status window into manuscript-level aging-mechanism, model-system, ARRIVE, marker-validation, and routing decisions they can act on while waiting.

For the aging biology landscape beyond Aging Cell, start with the Aging Cell submission guidelines guide, then compare Journal of Cell Biology under review, EMBO Journal under review, and eLife under review for neighboring cell-biology and reviewed-preprint routes. The choice across these titles depends on whether the central contribution is top aging biology mechanism, neuro-aging, geriatric science, metabolic aging, cell-biological mechanism, or Reviewed Preprint fit.

Reviewers at Aging Cell typically draw from 2 to 3 aging biology subspecialty experts under the Wiley single-blind Supervising Editor model. Editors screen and triage manuscripts before any reviewer sees them, and preparing a response template that addresses aging biology mechanism and methodology accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Aging Cell aging-biology-mechanism bar before submission, our Aging Cell pre-submission diagnostic flags the framing and methodology weaknesses most likely to surface in reviewer reports.